Low-molecular-weight heparin in patients with chronic renal insufficiency

Internal and Emergency Medicine

Volumn 3, Issue 4, 2008, Pages 319-323

  Lim, Wendy ^a  

^a ST JOSEPH S HOSPITAL   (Canada)

Author keywords

Accumulation; Bleeding; Low molecular weight heparin; Renal insufficiency; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN;

BLEEDING; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; DRUG EFFECT; HUMAN; KIDNEY; METABOLISM; REVIEW; RISK FACTOR; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 55949089670     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-008-0164-9     Document Type: Review

References (24)

1. van Dongen CJ, van den Belt AG, Prins MH et al (2004) Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 4:CD001100
2. G Simonneau H Sors B Charbonnier 1997 A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism N Engl J Med 337 663 669
3. DJ Quinlan A McQuillan JW Eikenboom 2004 Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism Ann Intern Med 140 175 183
4. J Hirsh R Raschke 2004 Heparin and low-molecular-weight-heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy Chest 126 188S 203S
5. MM Koopman P Prandoni F Piovella 1996 Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home N Engl J Med 334 682 687
6. IG Schraibman AA Milne EM Royle 2001 Home versus in-patient treatment for deep vein thrombosis Nurs.Times 97 35
7. Kidney Disease Outcome Quality Initiative 2002 K/DOQI clinical practice guidelines for chronic renal disease: evaluation, classification, and stratification Am J Kidney Dis 39 S1 S46
8. Douketis J, Cook D, Meade M et al (2008) Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics. The DIRECT (Dalteparin's Influence on REnally Compromised anti-Ten-A) study. Arch Intern Med (in press)
9. CS Landefeld RJ Beyth 1993 Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention Am J Med 95 315 328
10. I Mahe M Aghassarian L Drouet 2007 Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study Thromb Haemost 97 581 586
11. I Mahe I Gouin-Thibault L Drouet 2007 Elderly medical patients treated with prophylactic dosages of enoxaparin: influence of renal function on anti-Xa activity level Drugs Aging 24 63 71
12. E Tincani C Mannucci B Casolari 2006 Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study Haematologica 91 976 979
13. W Lim F Dentali JW Eikelboom 2006 Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency Ann Intern Med 144 673 684
14. C Falga JA Capdevila S Soler 2007 Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry Thromb Haemost 98 771 776
15. JJ Santopinto KA Fox RJ Goldberg 2003 Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE) Heart 89 1003 1008
16. JP Collet G Montalescot G Agnelli 2005 Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events Eur Heart J 26 2285 2293
17. V Siguret E Pautas M Fevrier 2000 Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days Thromb Haemost 84 800 804
18. E Pautas I Gouin O Bellot 2002 Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients Drug Safety 25 725 733
19. LM Cook SR Kahn J Goodwin 2007 Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical practice J Thromb Haemost 5 937 941
20. KP Alexander AY Chen MT Roe 2005 Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes JAMA 294 3108 3116
21. NM LaPointe AY Chen KP Alexander 2007 Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes Arch Intern Med 167 1539 1544
22. Aventis Pharma Inc (2004) Lovenox product monograph (enoxaparin sodium)
23. KA Fox EM Antman G Montalescot 2007 The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial J Am Coll Cardiol 49 2249 2255
24. T Lachish B Rudensky I Slotki 2007 Enoxaparin dosage adjustment in patients with severe renal failure: antifactor xa concentrations and safety Pharmacotherapy 27 1347 1352